Successful Third Hematopoietic Stem Cell Transplantation for Blast Crisis of Chronic Myeloid Leukemia After Two Times of Graft Failure
DOI:
https://doi.org/10.17140/IMOJ-1-104Keywords:
Third stem cell transplantation, Graft failure, Chronic myelogenous leukemia, Acute promyelocytic leukemiaAbstract
Background: Chronic Myeloid Leukemia (CML) is largely treated with BCR-ABL protein targeted drugs called tyrosine kinase inhibitors (TKIs) , imatinib, which have led to dramatical improvement in 2001. Nilotinib and dasatinib were approved as the second new TK inhibitor in 2010, and Radotinib in 2012. However, the only curative treatment for CML is a bone marrow transplant or an allogeneic stem cell transplant.
Case: A 42-year-old man was diagnosed CML in June 2011. He had achieved complete cytogenetic response in 5 months later by nilotinib treatment. It did not lead to major molecular response in the 18th month, and blastic phase of acute promyelocytic leukemia (M3) occurred in the 19th months. Leukemia cells had both promyelocytic leukemia gene/retinoic acid receptor alpha (PML/RARα) and BCR/ABL translocations. A retinoic acid was administered for M3. The dasatinib was administered for the blast crisis, and remission was obtained.
Transplantation: Hematopoietic stem cell transplantation (HSCT) from umbilical cord blood was performed at remission, but it was rejected twice. The third HSCT was succeeded from a sister who had hyperthyroidism.
Conclusion: After 2 times of graft failures, HSCT was succeeded. Long plan of treatment is necessary for middle aged CML patients.
References
Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management. Am J Hematol. 2014; 89(5): 547-556. doi: 10.1002/ajh.23691
Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006; 108(6): 1809-1820. doi: 10.1182/ blood-2006-02-005686
Guardiola P, Kuentz M, Garban F, et al. Second early allogeneic stem cell transplantations for graft failure in acute leukaemia, chronic myeloid leukaemia and aplastic anaemia. French Society of Bone Marrow Transplantation. Br J Haematol. 2000; 111(1): 292-302. doi: 10.1111/j.1365-2141.2000.02306.x
Kanda J, Horwitz ME, Long GD, et al. Outcomes of a 1-day nonmyeloablative salvage regimen for patients with primary graft failure after allogeneic hematopoietic cell transplantation. Bone marrow transplantation. 2012; 47(5): 700-705. doi: 10.1038/bmt.2011.158
Nagamura-Inoue T, Kai S, Azuma H, et al. Unrelated cord blood transplantation in CML: Japan Cord Blood Bank Network analysis. Bone Marrow Transplantation. 2008; 42(4): 241-251. doi: 10.1038/bmt.2008.164
Kanda Y, Sakamaki H, Sao H, et al. Effect of conditioning regimen on the outcome of bone marrow transplantation from an unrelated donor. Biol Blood Marrow Transplant. 2005; 11(11): 881-889. doi: 10.1016/j.bbmt.2005.07.005
Socie G, Clift RA, Blaise D, et al. Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: Long-term follow-up of 4 randomized studies. Blood. 2001; 98(13): 3569-3574. doi: 10.1182/blood.V98.13.3569
Bredeson C, LeRademacher J, Kato K, et al. Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation. Blood. 2013; 122(24): 3871-3878. doi: 10.1182/blood-2013-08-519009
Andersson BS, Kashyap A, Gian V, et al. Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: A phase II study. Biol Blood Marrow Transplant. 2002; 8(3): 145-154. doi: 10.1053/bbmt.2002.v8.pm11939604
Kashyap A, Wingard J, Cagnoni P, et al. Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: Decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality. Biol Blood Marrow Transplant. 2002; 8(9): 493-500. doi: 10.1053/bbmt.2002.v8.pm12374454
Chewning JH, Castro-Malaspina H, Jakubowski A, et al. Fludarabine-based conditioning secures engraftment of second hematopoietic stem cell allografts (HSCT) in the treatment of initial graft failure. Biol Blood Marrow Transplant. 2007; 13(11): 1313-1323. doi: 10.1016/j.bbmt.2007.07.006
Byrne BJ, Horwitz M, Long GD, et al. Outcomes of a second non-myeloablative allogeneic stem cell transplantation following graft rejection. Bone marrow transplantation. 2008; 41(1): 39-43. doi: 10.1038/sj.bmt.1705882
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Internal Medicine (IMOJ) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.